DK2134702T4 - Krystallinske former af 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazol til anvendelse ved behandlingen af abnorm cellevækst i et pattedyr - Google Patents
Krystallinske former af 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazol til anvendelse ved behandlingen af abnorm cellevækst i et pattedyr Download PDFInfo
- Publication number
- DK2134702T4 DK2134702T4 DK08719405.6T DK08719405T DK2134702T4 DK 2134702 T4 DK2134702 T4 DK 2134702T4 DK 08719405 T DK08719405 T DK 08719405T DK 2134702 T4 DK2134702 T4 DK 2134702T4
- Authority
- DK
- Denmark
- Prior art keywords
- phenylsulfanyl
- methylcarbamoyl
- indazole
- ethenyl
- pyridin
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
- WRSXUNSJGJUKHE-UHFFFAOYSA-N indazole Chemical compound C1=CC=C[C]2C=NN=C21 WRSXUNSJGJUKHE-UHFFFAOYSA-N 0.000 title 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 title 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91037907P | 2007-04-05 | 2007-04-05 | |
US97654607P | 2007-10-01 | 2007-10-01 | |
US3155408P | 2008-02-26 | 2008-02-26 | |
PCT/IB2008/000792 WO2008122858A2 (en) | 2007-04-05 | 2008-03-25 | Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals |
Publications (2)
Publication Number | Publication Date |
---|---|
DK2134702T3 DK2134702T3 (da) | 2017-08-21 |
DK2134702T4 true DK2134702T4 (da) | 2023-09-25 |
Family
ID=39831473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08719405.6T DK2134702T4 (da) | 2007-04-05 | 2008-03-25 | Krystallinske former af 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazol til anvendelse ved behandlingen af abnorm cellevækst i et pattedyr |
Country Status (23)
Country | Link |
---|---|
US (1) | US8791140B2 (da) |
EP (4) | EP4249063A3 (da) |
JP (2) | JP5869197B2 (da) |
KR (1) | KR101237588B1 (da) |
CN (2) | CN101679356A (da) |
AR (1) | AR065931A1 (da) |
AU (1) | AU2008236444B2 (da) |
BR (1) | BRPI0809471A2 (da) |
CA (1) | CA2682859C (da) |
CY (1) | CY1119119T1 (da) |
DK (1) | DK2134702T4 (da) |
ES (2) | ES2919351T3 (da) |
FI (1) | FI2134702T4 (da) |
HK (1) | HK1193405A1 (da) |
IL (1) | IL201320A (da) |
MX (1) | MX2009010761A (da) |
NZ (1) | NZ580126A (da) |
PL (1) | PL2134702T5 (da) |
PT (1) | PT2134702T (da) |
RU (1) | RU2518898C2 (da) |
SI (1) | SI2134702T2 (da) |
TW (1) | TWI481602B (da) |
WO (1) | WO2008122858A2 (da) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ580126A (en) * | 2007-04-05 | 2012-03-30 | Pfizer Prod Inc | Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals |
WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
JO3062B1 (ar) * | 2010-10-05 | 2017-03-15 | Lilly Co Eli | R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري |
SG11201400145VA (en) * | 2011-09-30 | 2014-03-28 | Pfizer | Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide |
KR20140088556A (ko) | 2011-11-11 | 2014-07-10 | 화이자 인코포레이티드 | 만성 골수성 백혈병을 치료하기 위한 n-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일설파닐]-벤즈아미드 |
AU2013208324B2 (en) | 2012-01-13 | 2017-11-23 | Xspray Microparticles Ab | A pharmaceutical composition comprising stable, amorphous hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component |
US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
CN104230886A (zh) * | 2013-06-24 | 2014-12-24 | 南京华威医药科技开发有限公司 | 阿昔替尼新晶型 |
WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
CN104650034A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 一种稳定的阿西替尼化合物 |
SG11201605824XA (en) | 2014-02-04 | 2016-08-30 | Pfizer | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer |
ES2647262T3 (es) * | 2014-03-31 | 2017-12-20 | Senju Pharmaceutical Co. Ltd | Derivado de alquinil indazol y uso del mismo |
US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
EP3262073A1 (en) | 2015-02-26 | 2018-01-03 | Merck Patent GmbH | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
WO2016178150A1 (en) * | 2015-05-05 | 2016-11-10 | Shilpa Medicare Limited | Novel polymorphs of axitinib |
IL256245B (en) | 2015-06-16 | 2022-09-01 | Merck Patent Gmbh | Treatments that combine a pd-l1 antagonist |
CA3025049A1 (en) * | 2016-05-16 | 2017-11-23 | Pulmagen Therapeutics (Asthma) Limited | Crystal of quinoline derivative |
KR20190062515A (ko) | 2016-10-06 | 2019-06-05 | 화이자 인코포레이티드 | 암의 치료를 위한 아벨루맙의 투약 용법 |
CN106883212A (zh) * | 2017-03-16 | 2017-06-23 | 合肥拓锐生物科技有限公司 | 一种xli晶型阿昔替尼的制备方法 |
US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
US20220226246A1 (en) | 2019-05-09 | 2022-07-21 | Synthon B.V. | Pharmaceutical composition comprising axitinib |
CN111187253B (zh) * | 2020-01-09 | 2023-05-09 | 鲁南制药集团股份有限公司 | 一种阿昔替尼新晶型 |
BR112022018815A2 (pt) | 2020-03-25 | 2022-11-29 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor de tirosina cinase |
WO2022000265A1 (zh) * | 2020-06-30 | 2022-01-06 | 天津理工大学 | 一种阿西替尼与戊二酸共晶及其制备方法 |
CN113943270B (zh) * | 2020-07-15 | 2023-05-09 | 鲁南制药集团股份有限公司 | 一种阿昔替尼晶型 |
CN113943271B (zh) * | 2020-07-15 | 2023-11-14 | 鲁南制药集团股份有限公司 | 一种阿昔替尼晶型及其制备方法 |
CN114685436B (zh) * | 2020-12-25 | 2022-12-02 | 鲁南制药集团股份有限公司 | 阿昔替尼糖精共晶水合物 |
CN114685437B (zh) * | 2020-12-25 | 2022-12-09 | 鲁南制药集团股份有限公司 | 阿昔替尼与糖精共晶 |
CN114685431B (zh) * | 2020-12-26 | 2022-11-29 | 鲁南制药集团股份有限公司 | 一种阿昔替尼柠檬酸盐晶型 |
CN114685432B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 阿昔替尼盐晶型及其制备方法 |
CN114685435B (zh) * | 2020-12-28 | 2023-01-31 | 鲁南制药集团股份有限公司 | 阿昔替尼马来酸盐晶型及其制备 |
CN114685434B (zh) * | 2020-12-28 | 2023-06-16 | 鲁南制药集团股份有限公司 | 一种阿昔替尼与戊二酸共晶 |
CN114685433B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 一种阿昔替尼香草酸共晶盐及其制备 |
WO2023166420A1 (en) | 2022-03-03 | 2023-09-07 | Pfizer Inc. | Multispecific antibodies and uses thereof |
EP4282415A1 (en) | 2022-05-26 | 2023-11-29 | Genepharm S.A. | A stable tablet composition of axitinib |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
JP2003519698A (ja) † | 2000-01-07 | 2003-06-24 | トランスフォーム ファーマスーティカルズ,インコーポレイテッド | 多様な固体形態のハイスループットでの形成、同定および分析 |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
EP1613320A1 (en) | 2003-04-03 | 2006-01-11 | Pfizer Inc. | Dosage forms comprising ag013736 |
JP2008518904A (ja) † | 2004-11-02 | 2008-06-05 | ファイザー・インク | 6−[2−(メチルカルバモイル)フェニルスルファニル]−3−e−[2−(ピリジン−2−イル)エテニル]インダゾールの多形体形態 |
CN101052633A (zh) | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
CN101094836A (zh) | 2004-11-02 | 2007-12-26 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
AU2005300311A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Methods for preparing indazole compounds |
BRPI0518203A2 (pt) | 2004-11-02 | 2009-03-10 | Pfizer | mÉtodos para preparaÇço de compostos indazol |
US20080274192A1 (en) | 2005-05-19 | 2008-11-06 | Pfizer Inc. | Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor |
NZ580126A (en) * | 2007-04-05 | 2012-03-30 | Pfizer Prod Inc | Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals |
SG11201400145VA (en) † | 2011-09-30 | 2014-03-28 | Pfizer | Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide |
-
2008
- 2008-03-25 NZ NZ580126A patent/NZ580126A/en unknown
- 2008-03-25 CN CN200880016453A patent/CN101679356A/zh active Pending
- 2008-03-25 EP EP23167662.8A patent/EP4249063A3/en active Pending
- 2008-03-25 CN CN201310662484.1A patent/CN103626739B/zh active Active
- 2008-03-25 DK DK08719405.6T patent/DK2134702T4/da active
- 2008-03-25 US US12/594,575 patent/US8791140B2/en active Active
- 2008-03-25 MX MX2009010761A patent/MX2009010761A/es active IP Right Grant
- 2008-03-25 ES ES17168752T patent/ES2919351T3/es active Active
- 2008-03-25 EP EP17168752.8A patent/EP3252047B1/en active Active
- 2008-03-25 RU RU2009136593/04A patent/RU2518898C2/ru active
- 2008-03-25 CA CA2682859A patent/CA2682859C/en active Active
- 2008-03-25 ES ES08719405T patent/ES2634866T5/es active Active
- 2008-03-25 KR KR1020097023066A patent/KR101237588B1/ko active IP Right Grant
- 2008-03-25 EP EP22171745.7A patent/EP4074702A1/en not_active Withdrawn
- 2008-03-25 PT PT87194056T patent/PT2134702T/pt unknown
- 2008-03-25 WO PCT/IB2008/000792 patent/WO2008122858A2/en active Application Filing
- 2008-03-25 AU AU2008236444A patent/AU2008236444B2/en active Active
- 2008-03-25 EP EP08719405.6A patent/EP2134702B2/en active Active
- 2008-03-25 FI FIEP08719405.6T patent/FI2134702T4/fi active
- 2008-03-25 PL PL08719405.6T patent/PL2134702T5/pl unknown
- 2008-03-25 BR BRPI0809471-3A patent/BRPI0809471A2/pt not_active Application Discontinuation
- 2008-03-25 SI SI200831821T patent/SI2134702T2/sl unknown
- 2008-04-03 AR ARP080101388A patent/AR065931A1/es not_active Application Discontinuation
- 2008-04-03 TW TW097112383A patent/TWI481602B/zh active
- 2008-04-03 JP JP2008096783A patent/JP5869197B2/ja active Active
-
2009
- 2009-10-01 IL IL201320A patent/IL201320A/en active IP Right Grant
-
2010
- 2010-06-09 HK HK14106750.1A patent/HK1193405A1/zh unknown
-
2014
- 2014-06-02 JP JP2014113765A patent/JP2014193900A/ja not_active Withdrawn
-
2017
- 2017-07-24 CY CY20171100790T patent/CY1119119T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2134702T4 (da) | Krystallinske former af 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazol til anvendelse ved behandlingen af abnorm cellevækst i et pattedyr | |
IL262075A (en) | Treatment of inflammatory diseases with the help of placental stem cells | |
EP2367512A4 (en) | LASER PROCESSING OF PHOTOCAUTERIZATION OF CRYSTALLINE | |
IL211176A0 (en) | Methods for the production of ips cells | |
IL232511A0 (en) | Sulfonylamide derivatives for the treatment of abnormal cellular development | |
DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
DK2135081T3 (da) | Fremgangsmåder i forbindelse med celleoverfladeglycosylering | |
DK2375907T3 (da) | Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller | |
DK2501692T3 (da) | Fremgangsmåde til fremstilling af dabigatranetexilat | |
DK2620493T3 (da) | Mesenkymale stamceller til behandling af CNS-sygdomme | |
IL202034A0 (en) | Heterocyclic indazole derivatives | |
ZA201003909B (en) | Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide | |
FR2920428B1 (fr) | Procede de dedoublement de sels de l'omeprazole | |
HK1160106A1 (en) | Process for the preparation of optically active (s)-(-)-2-(n-propylamino)- 5-methoxytetraline and (s)-(-)-2-(n-propylamino)-5-hydroxytetraline compounds (s)-(-)-2-(n-)-5-(s)-(-)-2-(n- )-5- | |
DK2215050T3 (da) | Fremgangsmåde til fremstilling af 2-hydroxy-5-phenylalkylaminobenzoesyrederivater og salte deraf | |
EP2203441A4 (en) | PROCESS FOR OPTICALLY ACTIVE SULFOXIDE COMPOUNDS | |
FI20085707A0 (fi) | Menetelmä pienikiteisen titaanioksidin valmistamiseksi | |
EP2387402A4 (en) | METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS | |
GB0813270D0 (en) | Process of preparing optically active B-hydroxycarboxylic acid derivative | |
BRPI0813959A2 (pt) | Soluções oftálmicas estabilizadas | |
ZA200906990B (en) | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals | |
EP2251431A4 (en) | PROCESS FOR PRODUCING OPTICALLY ACTIVE INDOLINE-2-CARBOXYLIC ACID OR A DERIVATIVE THEREOF | |
IL244553B (en) | Altered placental cells | |
CN300844181S (zh) | 用于眼镜的铰接件 | |
CN300846423S (zh) | 用于眼镜的铰接件 |